AE-941, a standardized shark cartilage, does not improve lung cancer survival

Links shared publicly online about this topic.

1,139
total visits

AE-941, a standardized shark cartilage, does not improve lung cancer survival

The anti-cancer drug AE-941, a shark cartilage derivative, did not improve overall survival in patients with inoperable stage III non-small cell lung cancer, according to a study published online May 26 in the Journal of the National Cancer Institute.

View full resource at physorg.com

Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lung, Drug

Most Recently Shared on May 26, 2010 at 11:59 pm By:

FightCancer

AE-941, a standardized shark cartilage, does not improve lung cancer survival http://bit.ly/bZ6fm8

2 years ago...

Retweet

Favorite

Also Shared By:

PhysOrg Health News

AE-941, a Standardized Shark Cartilage, Does Not Improve Lung Cancer Survival -- , 10.1093/jnci/djq221 -- JNCI Journal of the National Cancer Institute

jnci.oxfordjournals.org — “AE-941, a Standardized Shark Cartilage, Does Not Improve Lung Cancer Survival -- , 10.1093/jnci/djq221 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org

Most Recently Shared on May 27, 2010 at 4:47 pm By:

J Nat'l Cancer Inst Medical Journal and Oncology

Anti-angiogenic shark cartilage derivative shown not to improve stage III non-small cell lung cancer survival. http://tinyurl.com/36m9ya5

2 years ago...

Retweet

Favorite

AE-941, a standardized shark cartilage, does not improve lung cancer survival

physorg.com — “The anti-cancer drug AE-941, a shark cartilage derivative, did not improve overall survival in patients with inoperable stage III non-small cell lung cancer, according to a study published online May 26 in the Journal of the National Cancer Institute.” View full resource at physorg.com